Title | Type | SJR | H index | Total Docs. (1999) | Total Docs. (3years) | Total Refs. (1999) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (1999) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Pharmacology and Toxicology, Supplement | journal | 0.138 Q3 | 7 | 1 | 40 | 389 | 16 | 40 | 0.40 | 389.00 | |
2 | Critical Reviews in Toxicology | journal | 2.039 Q1 | 129 | 13 | 53 | 2887 | 295 | 52 | 4.58 | 222.08 | |
3 | Alkaloids: Chemical and Biological Perspectives | book series | 0.772 Q2 | 15 | 11 | 22 | 2316 | 26 | 10 | 0.78 | 210.55 | |
4 | Progress in Medicinal Chemistry | journal | 0.657 Q1 | 38 | 7 | 20 | 1411 | 37 | 12 | 1.25 | 201.57 | |
5 | Reviews of Physiology Biochemistry and Pharmacology | journal | 3.271 Q1 | 70 | 31 | 22 | 5954 | 143 | 22 | 8.20 | 192.06 | |
6 | Natural Product Reports | journal | 2.402 Q1 | 211 | 42 | 96 | 6961 | 435 | 96 | 4.50 | 165.74 | |
7 | Progress in Drug Research | book series | 0.725 Q1 | 46 | 11 | 45 | 1760 | 81 | 43 | 2.03 | 160.00 | |
8 | Reviews in Toxicology | journal | 0.404 Q3 | 21 | 8 | 58 | 1071 | 51 | 57 | 0.88 | 133.88 | |
9 | Expert Opinion on Therapeutic Targets | journal | 0.123 Q4 | 106 | 40 | 118 | 4160 | 9 | 116 | 0.08 | 104.00 | |
10 | Cellular and Molecular Life Sciences | journal | 1.724 Q1 | 261 | 227 | 449 | 21816 | 1104 | 447 | 2.92 | 96.11 | |
11 | Advanced Drug Delivery Reviews | journal | 0.978 Q1 | 366 | 102 | 348 | 9151 | 868 | 326 | 2.15 | 89.72 | |
12 | Expert Opinion on Investigational Drugs | journal | 0.348 Q2 | 117 | 155 | 426 | 12075 | 435 | 418 | 1.06 | 77.90 | |
13 | Epitheorese Klinikes Farmakologias kai Farmakokinetikes | journal | 0.100 Q4 | 5 | 8 | 44 | 607 | 0 | 44 | 0.00 | 75.88 | |
14 | Journal of Toxicology and Environmental Health - Part B: Critical Reviews | journal | 0.608 Q2 | 99 | 12 | 14 | 900 | 30 | 14 | 2.14 | 75.00 | |
15 | Advances in Antiviral Drug Design | book series | 1.023 Q1 | 12 | 7 | 7 | 519 | 23 | 5 | 0.00 | 74.14 | |
16 | Clinical Pharmacokinetics | journal | 1.586 Q1 | 184 | 81 | 186 | 5697 | 1014 | 178 | 5.21 | 70.33 | |
17 | Drug Safety | journal | 0.795 Q1 | 140 | 92 | 208 | 6358 | 598 | 202 | 2.83 | 69.11 | |
18 | Expert Opinion on Emerging Drugs | journal | 0.264 Q3 | 54 | 20 | 43 | 1380 | 34 | 42 | 0.79 | 69.00 | |
19 | BioDrugs | journal | 0.226 Q3 | 79 | 79 | 272 | 5247 | 182 | 257 | 0.65 | 66.42 | |
20 | Investigational New Drugs | journal | 0.720 Q1 | 97 | 38 | 143 | 2490 | 301 | 142 | 2.01 | 65.53 | |
21 | EOS Rivista di Immunologia ed Immunofarmacologia | journal | 0.141 Q3 | 5 | 23 | 48 | 1457 | 4 | 46 | 0.11 | 63.35 | |
22 | Toxicology and Industrial Health | journal | 0.376 Q3 | 69 | 73 | 158 | 4477 | 177 | 157 | 1.20 | 61.33 | |
23 | Adverse Drug Reactions and Toxicological Reviews | journal | 0.197 Q3 | 25 | 15 | 51 | 919 | 35 | 40 | 0.79 | 61.27 | |
24 | Side Effects of Drugs Annual | book series | 0.101 Q4 | 9 | 51 | 102 | 3092 | 2 | 102 | 0.02 | 60.63 | |
25 | IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer | book series | 0.236 Q3 | 50 | 142 | 45 | 8141 | 25 | 45 | 1.17 | 57.33 | |
26 | Current Opinion in Molecular Therapeutics | journal | 67 | 93 | 0 | 5163 | 0 | 0 | 0.00 | 55.52 | ||
27 | Expert Opinion on Pharmacotherapy | journal | 93 | 16 | 0 | 861 | 0 | 0 | 0.00 | 53.81 | ||
28 | Drugs of Today | journal | 0.203 Q3 | 57 | 102 | 273 | 5395 | 128 | 272 | 0.40 | 52.89 | |
29 | Toxin Reviews | journal | 0.205 Q4 | 54 | 24 | 93 | 1269 | 57 | 88 | 0.60 | 52.88 | |
30 | Cytokines, Cellular and Molecular Therapy | journal | 0.670 Q1 | 28 | 26 | 56 | 1337 | 101 | 55 | 1.80 | 51.42 | |
31 | Apoptosis : an international journal on programmed cell death | journal | 0.700 Q1 | 128 | 48 | 130 | 2463 | 202 | 130 | 1.44 | 51.31 | |
32 | Antiviral Chemistry and Chemotherapy | journal | 0.497 Q2 | 59 | 32 | 176 | 1616 | 306 | 175 | 1.79 | 50.50 | |
33 | Mutation Research - DNA Repair | journal | 2.292 Q1 | 75 | 64 | 210 | 3172 | 656 | 210 | 3.01 | 49.56 | |
34 | Journal of Computer-Aided Molecular Design | journal | 1.113 Q1 | 119 | 70 | 233 | 3462 | 567 | 233 | 2.41 | 49.46 | |
35 | Neuropsychopharmacology | journal | 2.634 Q1 | 249 | 176 | 309 | 8662 | 1624 | 291 | 4.69 | 49.22 | |
36 | Neuropharmacology | journal | 2.249 Q1 | 191 | 182 | 563 | 8527 | 2242 | 556 | 4.05 | 46.85 | |
37 | Drugs of the Future | journal | 0.209 Q3 | 46 | 100 | 1336 | 4625 | 350 | 1285 | 0.39 | 46.25 | |
38 | International Journal of Neuropsychopharmacology | journal | 0.324 Q2 | 125 | 40 | 26 | 1850 | 20 | 26 | 0.77 | 46.25 | |
39 | Trends in Pharmacological Sciences | journal | 4.514 Q1 | 244 | 102 | 304 | 4699 | 2317 | 233 | 8.20 | 46.07 | |
40 | Current Opinion in Drug Discovery and Development | journal | 1.523 Q1 | 85 | 68 | 15 | 3096 | 67 | 15 | 4.47 | 45.53 | |
41 | Anales de la Real Academia Nacional de Farmacia (discontinued) | journal | 0.112 Q4 | 10 | 15 | 39 | 682 | 2 | 39 | 0.08 | 45.47 | |
42 | Antiviral Research | journal | 0.703 Q1 | 151 | 70 | 217 | 3183 | 441 | 216 | 1.98 | 45.47 | |
43 | Biomedicine and Pharmacotherapy | journal | 0.290 Q3 | 149 | 74 | 231 | 3319 | 170 | 201 | 0.79 | 44.85 | |
44 | Receptors and Channels | journal | 1.182 Q1 | 44 | 21 | 78 | 923 | 148 | 78 | 1.65 | 43.95 | |
45 | IDrugs : the investigational drugs journal | journal | 0.237 Q3 | 39 | 183 | 58 | 7804 | 20 | 58 | 0.34 | 42.64 | |
46 | Psychopharmacology | journal | 1.687 Q1 | 214 | 393 | 936 | 16557 | 3330 | 907 | 3.02 | 42.13 | |
47 | Expert Opinion on Therapeutic Patents | journal | 0.356 Q2 | 88 | 143 | 398 | 6018 | 323 | 394 | 1.02 | 42.08 | |
48 | Drug News and Perspectives | journal | 0.208 Q3 | 53 | 60 | 208 | 2509 | 93 | 200 | 0.45 | 41.82 | |
49 | Revista Portuguesa de Farmacia | journal | 0.131 Q3 | 5 | 21 | 69 | 878 | 9 | 69 | 0.13 | 41.81 | |
50 | Journal of Molecular Medicine | journal | 2.632 Q1 | 157 | 137 | 315 | 5701 | 1289 | 291 | 3.33 | 41.61 |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®